In short
This article explores a clinical trial investigating the effectiveness of Eprosartan Mesilate in treating essential hypertension. The study compares a new formulation of eprosartan with the currently marketed eprosartan tablet to determine if they have equivalent blood pressure-lowering effects. This research is crucial for understanding the potential benefits of this medication for patients with mild to moderate essential hypertension.
At a glance
- Study Type
- Prospective, randomized, double-blind, parallel-group study
- Condition Studied
- Mild to moderate essential hypertension
- Main Drugs
- Eprosartan (450 mg) and Eprosartan Mesylate (600 mg)
- Primary Outcome
- Change in sitting diastolic blood pressure (DBP) from baseline
- Study Goal
- To demonstrate equivalent efficacy in blood pressure lowering effects
- Treatment Groups
- 1) Eprosartan + Placebo Eprosartan Mesylate; 2) Eprosartan Mesylate + Placebo Eprosartan
What is Eprosartan Mesylate?
Eprosartan Mesylate is a medication that belongs to a class of drugs known as angiotensin receptor blockers (ARBs). These drugs are widely used and have proven effectiveness in lowering blood pressure. Eprosartan Mesylate is specifically designed to treat a condition called essential hypertension, which is the medical term for high blood pressure with no identifiable cause.
Medical Use
The primary use of Eprosartan Mesylate is in the treatment of mild to moderate essential hypertension. Hypertension is a condition where the force of blood against your artery walls is consistently too high, which can lead to various health problems if left untreated. By helping to lower blood pressure, Eprosartan Mesylate can reduce the risk of serious complications such as heart disease, stroke, and kidney problems.
How It Works
Eprosartan Mesylate works by blocking the action of a hormone called angiotensin II. This hormone causes blood vessels to narrow, which can increase blood pressure. By preventing angiotensin II from affecting blood vessels, Eprosartan Mesylate allows blood vessels to relax and widen, thereby lowering blood pressure.
Clinical Study
A clinical trial was conducted to compare the effectiveness of a new formulation of Eprosartan with the currently marketed Eprosartan Mesylate tablet. The study was designed as follows:
- Type of study: A prospective, randomized, double-blind, parallel-group study. This means that participants were randomly assigned to different groups, and neither the participants nor the researchers knew who was receiving which treatment during the study.
- Purpose: To compare the blood pressure-lowering effect of a new drug formulation of Eprosartan with the currently marketed Eprosartan Mesylate tablet.
- Primary outcome: The main goal was to assess the change in sitting diastolic blood pressure (DBP) from the beginning of the study (baseline) to the end. Diastolic blood pressure is the lower number in a blood pressure reading, which measures the pressure in your arteries when your heart is at rest between beats.
- Study groups: Participants were divided into two groups:
- One group received Eprosartan plus a placebo (inactive substance) designed to look like Eprosartan Mesylate.
- The other group received Eprosartan Mesylate plus a placebo designed to look like Eprosartan.
The aim of this study was to demonstrate that the new formulation of Eprosartan is equally effective in lowering blood pressure as the currently marketed Eprosartan Mesylate tablet.
Dosage and Formulation
In the clinical study, two different formulations were used:
- Eprosartan: A new formulation containing only the active ingredient Eprosartan, dosed at 450 mg.
- Eprosartan Mesylate: The currently marketed formulation, dosed at 600 mg.
It's important to note that the dosage and formulation you receive should be determined by your healthcare provider based on your individual needs and medical condition.
Alternative Names
Eprosartan Mesylate is also known by other names, which may include:
- ABT-139: This is likely a code name used during the drug's development phase.
- Teveten: This is a brand name under which Eprosartan Mesylate is marketed.
Your healthcare provider or pharmacist may use these alternative names when discussing this medication with you.